Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07325630 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Perioprative Study of IBI363 in Patients With MHC-II-Negative Locally Advanced Gastric Cancer

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated January 8, 2026 (before its estimated May 30, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
This is a phase 2 study designed to evaluate the safety and efficacy of IBI363 in combination with oxaliplatin and capecitabine (XELOX) or S-1 and oxaliplatin (SOX) in perioprative treatment of locally advanced MHC-II-negative gastric and gastroesophageal junction adenocarcinoma.
Trial Details
NCT Number NCT07325630
Lead Sponsor Zhejiang Cancer Hospital
Conditions
(from sponsor)		 IBI363 + Chemotherapy
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov